ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
An Interview with Dr. Alice Shaw at ALKtALK, Feb. 2022
Dr. Alice Shaw, MD, PhD, Boston, MA Global Head of Translational Clinical Oncology at Novartis Attending physician, Center for Thoracic Cancers at Massachussets General Hospital Associate Professor of medicine at Harvard Medical School Transcript of ALKtALK, February 6, 2022 Introduction I am from Maryland originally. Then, after high school, I came up here to Boston,…
-
LUNGevity Partners with ALK Positive to Award $1.5 Million in Lung Cancer Research Grants
FOR IMMEDIATE RELEASEMedia ContactColin Bartonmedical@alkpositive.org303-204-3388 WASHINGTON, DC (January 27, 2022) — LUNGevity Foundation is partnering for the third time with the patient-led registered nonprofit organization ALK Positive to support the ALK-Positive Lung Cancer Research Award Program. This year, the patient oncogene group will potentially fund research projects totaling up to $1.5 million over two years—their…
-
$7.6M Gift Launches New Lung Cancer Research Initiative at University of Michigan’s Rogel Cancer Center
EDITOR’S NOTE: This is a reprint of a press release from the University of Michigan’s Rogel Cancer Center – this $7.6 million gift from Judith L. Tam and the Richard Tam Foundation may be the largest made to-date specifically for ALK-positive research. The direct link to the release is here: Increased understanding of the genetic…
-
Stronger Together: The Latest from ALK Positive Inc.
ALK Positive, Inc. became a registered 501c3 (nonprofit) organization in March 2021. Both the ALK Positive Board of Directors and the ALK Positive Committees are comprised of volunteer members from the ALK Positive Support Group, all ALK-positive patients or caregivers themselves. The Board and Committees are all working together to improve the life expectancy and…
-
Understanding ALK structural data
“Know thy self, know thy enemy. A thousand battles, a thousand victories”; a quote by the famous Chinese historical figure Sun Tzu. Accordingly, scientists have been working hard at understanding the fundamentals of the ALK protein. Recently, a paper was published by a group of scientists in Belgium lead by Dr. Savvides, in which they described…
-
Clinical Trials Can Help Those with ALK Lung Cancer Get State of the Art Treatment
In this newsletter, we pay tribute to Linnea Olson, a 17-year ALK-positive lung cancer survivor. We lost her in November of 2021, but her legacy as a creative, kind, and impactful lung cancer advocate will always inspire our group. Linnea, along with many other long-term ALK-positive lung cancer survivors, participated in clinical trials at several…
-
Sequencing treatment in ALK-positive cancer
The proverbial question, “what is my best treatment option?” is always on a patient’s mind. With the current treatment options available to us, ALKies, “what should we do?” comes up often. There are all the TKI options (Crizotinib, Ceritinib, Ensartinib, Alectinib, Brigatinib, and Lorlatinib), chemotherapy, radiation therapy and surgery (depending on your stage). By…